AI Medical Compendium Journal:
BJUI compass

Showing 1 to 7 of 7 articles

Optilume drug-coated balloon for anterior urethral stricture: 2-year results of the ROBUST III trial.

BJUI compass
OBJECTIVE: The aim of this study is to report the updated 2-year results of the intervention arm of the ROBUST III randomized trial evaluating the safety and efficacy of the Optilume drug-coated balloon (DCB) versus standard endoscopic management of ...

Indocyanine green-marked fluorescence-guided off-clamp versus intraoperative ultrasound-guided on-clamp robotic partial nephrectomy: Outcomes on surgical procedure.

BJUI compass
OBJECTIVES: To compare surgical and functional outcomes between off-clamp robot-assisted partial nephrectomy with indocyanine-green tumour marking through preliminary superselective embolization and on-clamp robot-assisted partial nephrectomy with in...

Low PSA radiographic disease progression on C11-choline PET.

BJUI compass
BACKGROUND: For men with prostate cancer, radiographic progression may occur without a concordant rise in prostate-specific antigen (PSA). Our study aimed to assess the prevalence of radiographic progression using C-11 choline positron emission tomog...

Evaluation of Proclarix in the diagnostic work-up of prostate cancer.

BJUI compass
OBJECTIVES: The use of multiparametric magnetic resonance imaging (mpMRI) has been widely adopted in the diagnostic work-up for suspicious prostate cancer (PCa) and is recommended in most current guidelines. However, mpMRI lesions are often indetermi...

Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.

BJUI compass
OBJECTIVES: Multimodal kidney-preserving (MKP) strategies may be an option for patients with localised or locally advanced high-risk upper tract urothelial carcinoma (UTUC) who have a relative contraindication for nephroureterectomy (NU).

Impact of MRI/US fusion-guided prostate biopsy on biopsy-naïve patients: A single urologist's experience.

BJUI compass
OBJECTIVES: To report our experience with imaging-guided targeted prostate biopsy (IGTpBx) for patients undergoing initial prostate biopsy in a clinical setting.

Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma.

BJUI compass
OBJECTIVE: To investigate whether dose reductions in cisplatin due to renal dysfunction were associated with worse clinical outcomes in metastatic urothelial carcinoma (UC) patients.